Model Number 3CX*FX15RE40C |
Device Problem
Increase in Pressure (1491)
|
Patient Problem
No Known Impact Or Consequence To Patient (2692)
|
Event Date 05/26/2020 |
Event Type
malfunction
|
Manufacturer Narrative
|
Terumo has not received the device for evaluation; therefore, the investigation has yet to be completed.Terumo plans on submitting a follow-up report when the investigation is complete and when more information becomes available.(b)(4).
|
|
Event Description
|
The user facility reported to terumo cardiovascular that during cardiopulmonary bypass, there was a progressive increase in the pre oxygenation pressure.No known impact or consequence to patient.The product was not changed out.The surgery was completed successfully.
|
|
Manufacturer Narrative
|
This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on june 23, 2020.H3 (device evaluation anticipated by manufacturer - a second follow-up will be submitted upon completion of the investigation and/or submission of new information, thus tcvs references conclusions code 11).All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|
|
Event Description
|
New information received that post oxygenator value was 400mmhg.
|
|
Manufacturer Narrative
|
This follow-up report is submitted to fda in accord with applicable regulations.Upon further investigation of the reported event, the following information is new and/or changed: d10 (device availability - added date returned to manufacturer).G4 (date received by manufacturer).G7 (indication that this is a follow-up report).H2 (follow-up due to additional information).H3 (device evaluation anticipated by manufacturer - a third follow-up will be submitted upon completion of the investigation and/or submission of new information, thus tcvs references conclusions code 11.) all available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|
|
Manufacturer Narrative
|
This follow-up report is submitted to fda in accord with applicable regulations.The sample was visually inspected and did not find any anomalies, such as break, in appearance.The actual sample was rinsed, dried and built into a circuit with tube.Bovine blood (hct 35% and temp 37 degrees) was circulated in the circuit, while the pressure drop was determined at each flow rate.The obtained values were confirmed to meet the factory's specification.No obstructions was confirmed.The actual sample was flushed with physiological saline solution.No clot that could lead an increase in the pressure was found inside the actual sample.Review of the manufacturing record and the incoming inspection record of the involved product/lot # combination confirmed there were no indication of anomalies in them.The investigation result verified that the actual sample after having been rinsed was the normal product presenting no problem.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|
|
Search Alerts/Recalls
|